• Feedback
  • RSS Feed
  • Sitemap
Odisha News, Odisha Breaking News, Odisha Latest News || Ommcom News
  • Home
  • Odisha
  • Nation
  • World
  • Sports
  • Business
  • Entertainment
  • Videos
  • Science & Tech
  • Photo Gallery
  • ଓଡ଼ିଆରେ ପଢନ୍ତୁ
No Result
View All Result
  • Home
  • Odisha
  • Nation
  • World
  • Sports
  • Business
  • Entertainment
  • Videos
  • Science & Tech
  • Photo Gallery
  • ଓଡ଼ିଆରେ ପଢନ୍ତୁ
No Result
View All Result
Odisha News, Odisha Breaking News, Odisha Latest News || Ommcom News
Home World

India Begins Phase 3 Clinical Trial With 1st Indigenous Dengue Vaccine

OMMCOM NEWS by OMMCOM NEWS
August 14, 2024
in World
DENGUE

New Delhi: In a significant development, the Indian Council of Medical Research (ICMR) and Panacea Biotec on Wednesday announced they have started first-ever Phase 3 clinical trial for developing a dengue vaccine in India.

The landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.

The first participant in this trial was vaccinated at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS), Rohtak, according to the Ministry of Health and Family Welfare.

“The initiation of this Phase 3 clinical trial for India’s first indigenous dengue vaccine marks a critical advancement in our fight against dengue. It reflects our commitment to protecting our citizens from this pervasive disease and underscores India’s capabilities in vaccine research and development,” said J.P. Nadda, Union Minister of Health and Family Welfare.

Through this collaboration between ICMR and Panacea Biotec, “we are not only taking a step towards ensuring the health and well-being of our people but also reinforcing our vision of Atmanirbhar Bharat in the healthcare sector,” said the Minister.

In collaboration with ICMR, Panacea Biotec will conduct the Phase 3 clinical trial across 19 sites in 18 states and union territories, involving more than 10,335 healthy adult participants.

The trial, primarily funded by ICMR with partial support from Panacea Biotec, is set to follow up with participants for two years.

At the moment, there is no antiviral treatment or licensed vaccine against dengue in the country.

According to the government, the development of an effective vaccine is complex due to the need to achieve good efficacy for all four serotypes.

In India, all four serotypes of Dengue virus are known to circulate or co-circulate in many regions.

In February, Japanese drugmaker Takeda Pharmaceuticals said it is in discussions with the Indian regulator and will soon initiate bridging trials on 500 people in India, as it seeks approval of its dengue vaccine.

Meanwhile, Takeda’s dengue vaccine Qdenga, pre-approved by the WHO in May, has shown more than 50 per cent efficacy in reducing the number of cases, with lasting effects and a good safety profile, according to a review of 19 studies published in the journal Vaccines.

The government said that Panacea Biotec, one of three Indian companies to receive the strain, is at the most advanced stage of development.

The company has worked extensively on these strains to develop a full-fledged vaccine formulation and holds a process patent for this work. Phase 1 and 2 clinical trials of the Indian vaccine formulation were completed in 2018-19, yielding promising results.

According to data by the National Centre for Vector Borne Diseases Control, the country recorded 19,447 cases of dengue and 16 deaths till April 30, 2024.

(IANS)

Tags: dengue vaccine
ShareTweetSendSharePinShareSend
Previous Post

Tokyo Stocks End Higher Tracking Wall Street Gains

Next Post

Amid Strict Vigil, 16 Bangladeshis Held At Agartala Railway Station

Related Posts

World

US Acts Against Facilitators Of Illegal Immigration

May 19, 2025
World

Appreciate Netherland’s Strong Condemnation Of Pahalgam Attack: EAM Jaishankar In The Hague

May 19, 2025
World

Sudanese Officials Sound Alarm Over Civil War’s Devastating Impact On Museums, Archaeological Sites

May 19, 2025
World

If US Can Extradite Rana, Why Can’t Pakistan Hand Over Masood Azhar And Hafiz Saeed: India’s Ambassador To Israel

May 19, 2025
World

South Korean Police Plan Triple-Layered Security For Presidential Candidates

May 19, 2025
World

Bangladesh Army Chief To Address All ‘Available Officers’ On Tuesday: Reports

May 19, 2025
Next Post

Amid Strict Vigil, 16 Bangladeshis Held At Agartala Railway Station

Thailand Court Dismisses PM Srettha Thavisin Over Breach Of Ethics

Shastri Backs India For Historic Border-Gavaskar Trophy Hat-Trick

Khimji
  • Feedback
  • RSS Feed
  • Sitemap

© 2025 - Ommcom News. All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Home
  • Odisha
  • Nation
  • World
  • Sports
  • Business
  • Entertainment
  • Videos
  • Science & Tech
  • Photo Gallery
  • ଓଡ଼ିଆରେ ପଢନ୍ତୁ

© 2025 - Ommcom News. All Rights Reserved.